ALS drug development: reflections from the past and a way forward
- PMID: 19019302
- PMCID: PMC4514695
- DOI: 10.1016/j.nurt.2008.08.002
ALS drug development: reflections from the past and a way forward
Abstract
Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We present a critical overview of past clinical trials, how therapies are selected for testing in people, challenges with ALS clinical trial design and conduct, and ways to best move forward.
References
-
- Charcot J, Joffroy A. Deux cas d’atrophie musculaire progressive. Arch Physiol. 1869;2:354–367.
-
- Mitsumoto H, Chad D, Pioro E. Amyotrophic lateral sclerosis. New York: Oxford Press; 1998.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous